Mark  Plavsic net worth and biography

Mark Plavsic Biography and Net Worth

Insider of Fate Therapeutics
Dr. Mark Plavsic is Chief Technical Officer at Fate Therapeutics, overseeing the company’s cell therapy manufacturing, supply chain, and technical operations. Dr. Plavsic has more than 20 years of broad experience in process development and end-to-end product development of large scale commercial biologics. Prior to joining Fate Therapeutics, Dr. Plavsic served as Chief Technical Officer at Lysogene, a late stage clinical development gene therapy company with headquarters in Paris, France. Before joining Lysogene, Dr. Plavsic was SVP of CMC at Torque Therapeutics, Inc., and was Head of Product Biosafety at Genzyme/Sanofi, where he was responsible for process improvements and viral safety of all commercial biological products and associated manufacturing processes. Previously, Dr. Plavsic was in charge of gene therapy development at Genzyme, overseeing the upstream, downstream, formulation and analytical developments of viral vectors used in gene therapy applications. Before Genzyme, he held various senior leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies, Inc. Dr. Plavsic’s professional experience ranges from Europe, Australasia and USA, and his technical expertise spans across a wide spectrum of drug development and manufacturing activities, including critical animal origin raw materials, cell culture media, GMP QC testing, GLP non-clinical studies, process and analytical development, GMP manufacturing, contract manufacturing, and supply chain. Dr. Plavsic received his Ph.D. in Virology and Molecular Cell Biology, M.Sc. in Virology and Immunology, and Doctor of Veterinary Medicine (D.V.M.) degree from the University of Belgrade in Yugoslavia. He has a Board certification in Microbiology, subspeciality Virology, from the American College of Veterinary Microbiologists.

What is Mark Plavsic's net worth?

The estimated net worth of Mark Plavsic is at least $639,428.69 as of July 5th, 2022. Dr. Plavsic owns 127,123 shares of Fate Therapeutics stock worth more than $639,429 as of April 19th. This net worth approximation does not reflect any other investments that Dr. Plavsic may own. Learn More about Mark Plavsic's net worth.

How do I contact Mark Plavsic?

The corporate mailing address for Dr. Plavsic and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Mark Plavsic's contact information.

Has Mark Plavsic been buying or selling shares of Fate Therapeutics?

Mark Plavsic has not been actively trading shares of Fate Therapeutics over the course of the past ninety days. Most recently, Mark Plavsic sold 3,719 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $24.61, for a transaction totalling $91,524.59. Following the completion of the sale, the insider now directly owns 127,123 shares of the company's stock, valued at $3,128,497.03. Learn More on Mark Plavsic's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, Fate Therapeutics insiders bought shares 2 times. They purchased a total of 64,630 shares worth more than $285,823.60. In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 63,259 shares worth more than $278,392.35. The most recent insider tranaction occured on January, 29th when CFO Edward J Dulac III sold 1,849 shares worth more than $9,245.00. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 1/29/2024.

Mark Plavsic Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2022Sell3,719$24.61$91,524.59127,123View SEC Filing Icon  
See Full Table

Mark Plavsic Buying and Selling Activity at Fate Therapeutics

This chart shows Mark Plavsic's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $4.79
Low: $4.70
High: $5.11

50 Day Range

MA: $6.92
Low: $4.79
High: $8.35

2 Week Range

Now: $4.79
Low: $1.63
High: $8.83

Volume

2,689,483 shs

Average Volume

2,780,347 shs

Market Capitalization

$545.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66